Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with mavacamten under the National Health Act 1953, section 85 for adult patients with symptomatic obstructive HCM.
The PBS subsidises treatment with tafamidis under the National Health Act 1953, section 85 for patients with transthyretin amyloid cardiomyopathy.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing mavacamten and tafamidis.
Treatment specifics
To be eligible for PBS-subsidised treatment with mavacamten, patients must be treated by either a:
- cardiologist
- consultant physician with experience in the management of HCM.
To be eligible for PBS-subsidised treatment with tafamidis, patients must be treated by and the authority application completed by, either a:
- cardiologist
- consultant physician with experience in the management of amyloid disorders.
Authority applications
Mavacamten
Applying for initial treatment
Please note: You don’t need to complete this application in writing when you request PBS authority online.
Applications for initial authority approval to prescribe PBS-subsidised mavacamten to treat symptomatic obstructive HCM can be made either:
- using the Online PBS Authorities system
- in writing and use HPOS Form upload
- in writing and mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed symptomatic obstructive hypertrophic cardiomyopathy - mavacamten - initial authority application form
- relevant attachments.
Applying for initial grandfather treatment
Please note: You don’t need to complete this application in writing when you request PBS authority online.
Applications for initial grandfather authority approval to prescribe PBS-subsidised mavacamten to treat symptomatic obstructive HCM can be made either:
- using the Online PBS Authorities system
- in writing and use HPOS Form upload
- in writing and mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed symptomatic obstructive hypertrophic cardiomyopathy - mavacamten - initial grandfather authority application form
- relevant attachments.
Applying for continuing treatment
Applications for continuing authority approval to prescribe PBS-subsidised mavacamten to treat symptomatic obstructive HCM can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drug Programs enquiry line.
Tafamidis
Please note: You’ll get an immediate assessment when you request PBS authorities online.
Applying for initial treatment
AApplications for initial authority approval to prescribe PBS-subsidised tafamidis to treat transthyretin amyloid cardiomyopathy can be made either in:
- real time using the Online PBS Authorities system
- writing and use HPOS Form upload
- writing and mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed transthyretin amyloid cardiomyopathy - tafamidis - initial authority application form
- relevant attachments.
Applying for initial grandfather treatment
Applications for initial grandfather authority approval to prescribe PBS-subsidised tafamidis to treat transthyretin amyloid cardiomyopathy can be made either in:
- real time using the Online PBS Authorities system
- writing and use HPOS Form upload
- writing and mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed transthyretin amyloid cardiomyopathy - tafamidis - initial authority application form
- relevant attachments.
Applying for continuing treatment
Applications for continuing authority approval to prescribe PBS-subsidised tafamidis to treat transthyretin amyloid cardiomyopathy can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drug Programs enquiry line.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.